Premium
O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES
Author(s) -
Klein Gregory,
Delmar Paul,
Hofmann Carsten,
Abi-Saab Danielle,
Andjelkovic Mirjana,
Ristic Smiljana,
Voyle Nicola,
Seibyl John,
Marek Ken,
Martenyi Ferenc,
Baudler Monika,
Fontoura Paulo,
Doody Rachelle
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2380
Subject(s) - medicine , cohort , placebo , dosing , nuclear medicine , surgery , pathology , alternative medicine
doses of LY3002813 resulted in significant reductions in florbetapir F18 tracer uptake on PET by 3 months, with further reduction with repeat dosing over time. For the initial dosing cohorts, reductions in florbetapir F18 at 3 months were -11.8 (SD 21.1) centiloids after a single dose of 10 mg/kg IV (n1⁄47); -39.0 (SD 18.1) centiloids after a single dose of 20mg/kg IV (n1⁄47); and -44.5 (SD 24.3) centiloids for 10mg/kg IVadministered every two weeks (n1⁄410). In patients with up to 72 weeks of follow-up after completion of treatment, the reduced post-treatment florbetapir F18 PET SUVr levels were maintained, without returning to pre-dose baseline levels. Conclusions: LY3002813 demonstrates significant, rapid and sustained reduction in cortical amyloid plaque in Alzheimer’s patients.